Sign In

Sanjay Mistry

Vice President Venture Investments New Company Creation - Johnson & Johnson Innovation – JJDC Inc.

Sanjay Mistry is a senior investment professional and board member at TRex Bio, a biotechnology company. He brings extensive experience in venture investments and new company creation within the pharmaceutical and biotechnology sectors.

Professional Background

Sanjay Mistry currently serves as the Vice President of Venture Investments and New Company Creation at Johnson & Johnson Innovation – JJDC Inc.1 In this role, he focuses on identifying and developing new investment opportunities in the life sciences industry.

Board Positions

Mistry holds several board positions, including:

  • Director on the Board of Directors at TRex Bio3
  • Director at Rapport Therapeutics2
  • Observer at Manifest Technologies2

Education

Sanjay Mistry has a strong academic background in pharmacology and biology:

  • PhD in Pharmacology from the University of Aberdeen, UK4
  • MSc in Clinical Pharmacology from the University of Aberdeen, UK4
  • BSc in Applied Biology/Biomedical Sciences4

Recent Developments

In June 2024, Mistry shared news about TRexBio's collaboration with Lilly, announcing the initiation of a Phase 1 study of TRB-051 for autoimmune and inflammatory diseases.5 This demonstrates his active involvement in the company's strategic partnerships and drug development progress.

Sanjay Mistry's expertise in venture investments, coupled with his scientific background, makes him a valuable asset to TRex Bio's board of directors, contributing to the company's growth and development in the biotechnology sector.

Highlights

Aug 16 · linkedin

I just registered for RNA Leaders USA, taking place on September 4-5, 2024. Join me to accelerate innovation and commercialisation of #RNA therapeutics and vaccines #RNALeaders https://lnkd.in/gsMzjttC RNA Leaders

Jun 26 · linkedin

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases

TRexBio has earned a double-digit million dollar milestone payment and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones across partnered programs.

TRB-051 program is the first to enter the clinic under the Research Collaboration and License Agreement between TRexBio and Lilly Collaboration leveraged TRexBio’s Deep Biology Platform, which maps regulatory T cell (“Treg”) behavior in human tissue to identify and target immune-regulatory pathways for novel therapeutic development

https://lnkd.in/gBF9RpMJ

Related Questions

What are Sanjay Mistry's main responsibilities at TRex Bio?
How did Sanjay Mistry transition from Johnson & Johnson to TRex Bio?
What are some notable projects Sanjay Mistry has worked on at TRex Bio?
What is Sanjay Mistry's educational background?
How has Sanjay Mistry's experience at Rapport Therapeutics influenced his role at TRex Bio?
Sanjay Mistry
Sanjay Mistry, photo 1
Sanjay Mistry, photo 2
Add to my network

Location

San Diego, California, United States